Hyperpolarized Xe129
Phase 1Small molecule
Hyperpolarized Xe129 is one of 90 small molecule programs targeting Pulmonary Arterial Hypertension. It is currently in Phase 1.
4
Indications
10
Total Trials
8
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Nexavar
BayerPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Benadryl
PParkedale
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Hyperpolarized Xe129
UUniversity of Kansas Medical Center
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Disease1 trial
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Recruiting·—·Phase 1·NCT04624490·260 enrolled
5 more indications
Pulmonary Arterial Hypertension1 trial
Lung Disease1 trial
Regional Monitoring of CF Lung Disease
Recruiting·—·Phase 1·NCT06339593·60 enrolled
CAR1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hyperpolarized Xe129. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details